The HU CFAR Human Immune System Mouse Core is initiating a new voucher program to make its services, which have significant associated expenses, more accessible to junior HU CFAR investigators who have yet to receive substantial grant funding. These vouchers will cover the costs of the humanized mice that we generate, the costs of performing experiments with them (Core personnel perform all aspects of the experiments), and the costs of housing the mice while they are in these Read more about Human Immune System Mouse Core VOUCHERS RFP
The University of Washington Department of Global Health and the Center for AIDS and STD are accepting applications for the 25th Annual Principles of STD/HIV Research Course. The course will be held July 17-July 27, 2017 at the University of Washington in Seattle, Washington.
A Consortium of Harvard University, Boston University, Northwestern University, and University of New Mexico
Announcing a new, one-year NIH-funded opportunity for early-career investigatorsinterested in working in low-resource settings. The Harvard-BU-Northwestern-UNM Fogarty Partnership for Global Health Research Training provides supportive mentorship, research opportunities and a collaborative research environment for early stage investigators to enhance their global health research expertise and their careers.
What: Pilot grants will be awarded with funding up to $50k in total costs. The HU CFAR will provide matching funds of $10k for up to 2 applications chosen for funding. The investigator(s) will need to be a Harvard University CFAR affiliated investigator.
National Survey on HIV in the Black Community (NSHBC) The goal of the NSHBC was to develop and administer a survey focused on the cultural, psychosocial, and structural factors that are driving the HIV epidemic amongst Black individuals in the United States. By focusing solely and comprehensively on Black individuals this survey allowed for a more nuanced understanding of the root causes of HIV within our target population. The new knowledge that will be created will better explain persistent disparities in the HIV epidemic in the US and directly inform interventions and policy change Read more about National Survey on HIV in the Black Community (NSHBC) results from the HU CFAR Health Equity Scientific Working Group
The same standard of medical care will be key in globally combatting the rise of drug resistant strains of HIV. Access to testing for signs of viral resistance, tailored ART regimens, and more expensive and less toxic drugs are just some of the treatment advantages in developed nations. In countries such as Kenya, Zambia, Uganda, Nigeria, Tanzania and South Africa, the alarming trend of drug resistance has nothing to do with efforts on the part of an HIV patient to adhere to medication regimens, but on other factors of access and instability.